Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved..
Tacrolimus (FK506) is a calcineurin inhibitor and is an essential component of many immunosuppressive regimens. The oral bioavailability of tacrolimus may be affected by many factors, including patient age and gender, as well as by drug-drug interactions or genetic polymorphisms in drug metabolism. The dosing recommendations for pediatric allogeneic hematopoietic cell transplantation (alloHCT) recipients have been derived from tacrolimus use in adult solid-organ transplantation patients. Data describing the impact of conversion of i.v. tacrolimus to oral on the incidence of acute graft-versus-host disease (aGVHD) are limited in children after alloHCT. In this study, we describe the incidence of grades II to IV aGVHD after conversion from i.v. tacrolimus to oral tacrolimus and study the clinical factors associated with delayed achievement of therapeutic blood levels. In this retrospective analysis, 68 pediatric patients (median age, 6.7 years; range, .25 to 22 years), underwent alloHCT for malignant and nonmalignant diseases and received tacrolimus and mycophenolate mofetil for aGVHD prophylaxis. Among all patients, the median number of days to achieve therapeutic tacrolimus trough concentration (10 ng/mL to 20 ng/mL) was 7 days (range, 0 to 37 days). Twenty-two patients developed grades II to IV aGVHD and the cumulative incidence of grades II to IV aGVHD in all patients was 32.4% (standard error, .06). On multivariate analysis ethnicity (white versus others: odds ratio [OR], -4.5; 95% confidence interval [95% CI], 1.091 to 18.91; P = .038) and ≥ 10 days of subtherapeutic tacrolimus levels in first 30 days on i.v. (OR, -3.8; 95% CI, 1.276 to 11.43; P = .017) were significantly associated with delay in achieving therapeutic tacrolimus trough concentration. The impact of race/ethnicity on therapeutic tacrolimus trough concentration in pediatric alloHCT recipients should be further studied prospectively so that individualized dosing plans can be developed.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 22(2016), 5 vom: 20. Mai, Seite 957-61 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kolb, Michelle [VerfasserIn] |
---|
Links: |
---|
Themen: |
Allogeneic hematopoietic cell transplantation |
---|
Anmerkungen: |
Date Completed 16.12.2016 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.bbmt.2016.02.005 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM257505245 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM257505245 | ||
003 | DE-627 | ||
005 | 20231224182957.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.bbmt.2016.02.005 |2 doi | |
028 | 5 | 2 | |a pubmed24n0858.xml |
035 | |a (DE-627)NLM257505245 | ||
035 | |a (NLM)26880117 | ||
035 | |a (PII)S1083-8791(16)00110-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kolb, Michelle |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 16.12.2016 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. | ||
520 | |a Tacrolimus (FK506) is a calcineurin inhibitor and is an essential component of many immunosuppressive regimens. The oral bioavailability of tacrolimus may be affected by many factors, including patient age and gender, as well as by drug-drug interactions or genetic polymorphisms in drug metabolism. The dosing recommendations for pediatric allogeneic hematopoietic cell transplantation (alloHCT) recipients have been derived from tacrolimus use in adult solid-organ transplantation patients. Data describing the impact of conversion of i.v. tacrolimus to oral on the incidence of acute graft-versus-host disease (aGVHD) are limited in children after alloHCT. In this study, we describe the incidence of grades II to IV aGVHD after conversion from i.v. tacrolimus to oral tacrolimus and study the clinical factors associated with delayed achievement of therapeutic blood levels. In this retrospective analysis, 68 pediatric patients (median age, 6.7 years; range, .25 to 22 years), underwent alloHCT for malignant and nonmalignant diseases and received tacrolimus and mycophenolate mofetil for aGVHD prophylaxis. Among all patients, the median number of days to achieve therapeutic tacrolimus trough concentration (10 ng/mL to 20 ng/mL) was 7 days (range, 0 to 37 days). Twenty-two patients developed grades II to IV aGVHD and the cumulative incidence of grades II to IV aGVHD in all patients was 32.4% (standard error, .06). On multivariate analysis ethnicity (white versus others: odds ratio [OR], -4.5; 95% confidence interval [95% CI], 1.091 to 18.91; P = .038) and ≥ 10 days of subtherapeutic tacrolimus levels in first 30 days on i.v. (OR, -3.8; 95% CI, 1.276 to 11.43; P = .017) were significantly associated with delay in achieving therapeutic tacrolimus trough concentration. The impact of race/ethnicity on therapeutic tacrolimus trough concentration in pediatric alloHCT recipients should be further studied prospectively so that individualized dosing plans can be developed | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Allogeneic hematopoietic cell transplantation | |
650 | 4 | |a Pediatrics | |
650 | 4 | |a Tacrolimus levels | |
650 | 7 | |a Tacrolimus |2 NLM | |
650 | 7 | |a WM0HAQ4WNM |2 NLM | |
700 | 1 | |a Offer, Katharine |e verfasserin |4 aut | |
700 | 1 | |a Jin, Zhezhen |e verfasserin |4 aut | |
700 | 1 | |a Kahn, Justine |e verfasserin |4 aut | |
700 | 1 | |a Bhatia, Monica |e verfasserin |4 aut | |
700 | 1 | |a Kung, Andrew L |e verfasserin |4 aut | |
700 | 1 | |a Garvin, James H |e verfasserin |4 aut | |
700 | 1 | |a George, Diane |e verfasserin |4 aut | |
700 | 1 | |a Satwani, Prakash |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation |d 1998 |g 22(2016), 5 vom: 20. Mai, Seite 957-61 |w (DE-627)NLM090383915 |x 1523-6536 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2016 |g number:5 |g day:20 |g month:05 |g pages:957-61 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbmt.2016.02.005 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2016 |e 5 |b 20 |c 05 |h 957-61 |